A great advance in the treatment of Alzheimer’s?

(Boursier.com) — AB Science Announces that a new study evaluated by peers. Therefore, conducted by an independent research team based in China (pharmaceutical university of Guangdong and Sun Yat-Sen university) presents new evidence demonstrating that Masitinib offers a new promising approach for the treatment of Alzheimer’s disease, in particular its most common form, sporadic Alzheimer’s disease, which represents more than 95% of all cases.

Masitinib is a very innovative drug for the treatment of Alzheimer’s disease because. For example, unlike the majority of drugs developed for this indication, it targets the innate brain immune system, including mastocytes and microglies, the group explains. Therefore, The positioning of the Masitinib in the treatment of Alzheimer’s disease also differs from that of other drugs.

In this publication accessible online on the Revue website Neuroscience Letters (https://doi.org/10.1016/j.neulet.2025.138300), the researchers used a proven murin model reproducing the cognitive and behavioral symptoms of great advance treatment alzheimer’s? sporadic Alzheimer’s disease. In addition, Treaty in Masitinib. Meanwhile, mice have shown marked improvements in memory, learning, smell and anxious behavior, as many early indicators of the progression of Alzheimer’s disease.

This study also revealed that Masitinib: reduces toxic brain proteins such as hyperphosphorylated tau protein. mitigates synaptic dysfunctions and morphological lesions, that is to say that it protects synapses, essential to communication between brain cells; Removes microglial activation, which inhibit the NF-? B/NLRP3/Caspase-1 signaling axis. a key in inflammatory signaling cascade linked to Alzheimer’s disease, thus eliminating the brain inflammation of mice with Alzheimer’s disease.

Quoting…

The authors stressed that this is the first study demonstrating that the Masitinib attenuates the pathology of sporadic Alzheimer’s disease thanks to a double mechanism of cognitive improvement and neuroprotection.

Masitinib has already demonstrated its effectiveness in improving cognitive functions. synaptic integrity in a murin model of great advance treatment alzheimer’s? family Alzheimer’s disease. In addition, randomized studies, controlled by placebo, phase 2 and phase 2b/3 have shown that Masitinib (4.5 mg/kg/day) can effectively delay or slow down the progress of dementia. The results of clinical. preclinical studies have also been summarized in an article, whose authors conclude that “all studies have shown positive effects on cognitive functions in Alzheimer’s disease, with good tolerance overall”.

AB Science has already received an authorization from the American Food. Drug Administration (FDA) as well as several European countries to launch a phase III study (AB21004) in patients with Alzheimer’s disease. The AB21004 study is a phase 3 randomized double -blind study aimed at evaluating the tolerance. efficiency of Masitinib in patients with light Alzheimer’s disease, in combination with reference treatments, namely cholinesterase and/or memantine inhibitors. The study must recruit 600 patients.

Based on the results of the AB09004 study. AB Science has filed a patent application great advance treatment alzheimer’s? relating to methods of processing Alzheimer’s disease (that is to say a medical use patent) with its main molecule, the Masitinib (WO2022129410A1). If it is granted. this patent will ensure the protection of the intellectual property of the Masitinib in this indication until 2041. A similar strategy has been successfully applied in amyotrophic lateral sclerosis. with the grant of a medical use of medical use for Masitinib in the treatment of SLA on a global scale (press release of June 1, 2023).